Home › Companies › GENERATION BIO CO. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and GENERATION BIO CO.’s Form 8-K, filed June 7, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 6, 2024: 5 items on GENERATION BIO CO.’s Form 8-K, filed June 7, 2024: 2 approved · 3 passed (calculated).
Significant dissent: 1 director (25.7% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025
Explore GENERATION BIO CO. in the interactive database Compare manager voting policies
These tallies are GENERATION BIO CO.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 7, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jeffrey Jonas, M.D. | 35,807,200 | -- | -- | 12,353,347 | 5,410,328 | 74% | Passed (calculated) | — |
| Elect Director: Geoff McDonough, M.D. | 47,658,822 | -- | -- | 501,725 | 5,410,328 | 99% | Passed (calculated) | — |
| Elect Director: Donald Nicholson, Ph.D. | 47,589,073 | -- | -- | 571,474 | 5,410,328 | 99% | Passed (calculated) | — |
| 2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 | 53,562,165 | 1,795 | 6,915 | -- | -- | 99.9% | Approved | — |
| 3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers | 47,772,176 | 373,246 | 15,125 | -- | 5,410,328 | 99.2% | Approved | — |
Source: GENERATION BIO CO., Form 8-K, filed with the SEC on June 7, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
109 asset managers disclosed a vote on at least one GENERATION BIO CO. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Election of three Class I directors to our board of directors, each to serve until the 2027 Annual Meeting of Stockholders: Geoff McDonough
GENERATION BIO CO.’s own tally for this item (“Elect Director: Geoff McDonough, M.D.”): 47,658,822 for, 501,725 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 38 asset managers below reported 17,504,814 for, 322,141 withheld, 15,831 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 7,594,583 | 0 | 0 | 0 | For |
| Fidelity | 4,384,109 | 0 | 0 | 0 | For |
| Vanguard | 2,533,447 | 0 | 0 | 0 | For |
| BlackRock | 1,143,240 | 0 | 0 | 0 | For |
| Charles Schwab | 389,451 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 318,340 | Withhold |
| BRIDGEWAY FUNDS INC | 241,600 | 0 | 0 | 0 | For |
| Goldman Sachs | 219,730 | 0 | 0 | 0 | For |
| SEI | 215,561 | 0 | 0 | 0 | For |
| Equitable | 178,978 | 0 | 0 | 0 | For |
| TIAA | 148,392 | 0 | 0 | 0 | For |
| John Hancock | 101,820 | 0 | 4,046 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 79,184 | 0 | 0 | 0 | For |
| Managed Portfolio Series | 44,094 | 0 | 0 | 0 | For |
| Lincoln Financial | 39,000 | 0 | 0 | 2,510 | Mixed |
| AIG/SunAmerica | 22,317 | 0 | 0 | 0 | For |
| Northern Trust | 21,499 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 18,778 | 0 | 0 | 0 | For |
| Pacific Life | 18,619 | 0 | 0 | 0 | For |
| Nationwide | 17,332 | 0 | 0 | 0 | For |
| State Street | 16,681 | 0 | 0 | 0 | For |
| Voya | 16,253 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 12,800 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 11,785 | 0 | Abstain |
| American Century | 10,895 | 0 | 0 | 0 | For |
Showing the 25 largest of 38 asset managers. All 38 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Election of three Class I directors to our board of directors, each to serve until the 2027 Annual Meeting of Stockholders: Donald Nicholson
GENERATION BIO CO.’s own tally for this item (“Elect Director: Donald Nicholson, Ph.D.”): 47,589,073 for, 571,474 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 38 asset managers below reported 17,436,619 for, 390,336 withheld, 15,831 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 7,594,583 | 0 | 0 | 0 | For |
| Fidelity | 4,384,109 | 0 | 0 | 0 | For |
| Vanguard | 2,533,447 | 0 | 0 | 0 | For |
| BlackRock | 1,143,240 | 0 | 0 | 0 | For |
| Charles Schwab | 389,451 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 318,340 | Withhold |
| BRIDGEWAY FUNDS INC | 241,600 | 0 | 0 | 0 | For |
| Goldman Sachs | 219,730 | 0 | 0 | 0 | For |
| SEI | 215,561 | 0 | 0 | 0 | For |
| Equitable | 110,783 | 0 | 0 | 68,195 | Mixed |
| TIAA | 148,392 | 0 | 0 | 0 | For |
| John Hancock | 101,820 | 0 | 4,046 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 79,184 | 0 | 0 | 0 | For |
| Managed Portfolio Series | 44,094 | 0 | 0 | 0 | For |
| Lincoln Financial | 39,000 | 0 | 0 | 2,510 | Mixed |
| AIG/SunAmerica | 22,317 | 0 | 0 | 0 | For |
| Northern Trust | 21,499 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 18,778 | 0 | 0 | 0 | For |
| Pacific Life | 18,619 | 0 | 0 | 0 | For |
| Nationwide | 17,332 | 0 | 0 | 0 | For |
| State Street | 16,681 | 0 | 0 | 0 | For |
| Voya | 16,253 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 12,800 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 11,785 | 0 | Abstain |
| American Century | 10,895 | 0 | 0 | 0 | For |
Showing the 25 largest of 38 asset managers. All 38 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Description as filed by funds: Election of three Class I directors to our board of directors, each to serve until the 2027 Annual Meeting of Stockholders: Jeffrey Jonas
GENERATION BIO CO.’s own tally for this item (“Elect Director: Jeffrey Jonas, M.D.”): 35,807,200 for, 12,353,347 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 38 asset managers below reported 13,985,696 for, 3,773,930 withheld, 83,160 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 7,594,583 | 0 | 0 | 0 | For |
| Fidelity | 4,384,109 | 0 | 0 | 0 | For |
| Vanguard | 0 | 0 | 0 | 2,533,447 | Withhold |
| BlackRock | 1,143,240 | 0 | 0 | 0 | For |
| Charles Schwab | 389,451 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 318,340 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 241,600 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 219,730 | Withhold |
| SEI | 0 | 0 | 0 | 215,561 | Withhold |
| Equitable | 110,783 | 0 | 0 | 68,195 | Mixed |
| TIAA | 148,392 | 0 | 0 | 0 | For |
| John Hancock | 83,285 | 0 | 22,581 | 0 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 79,184 | 0 | 0 | 0 | For |
| Managed Portfolio Series | 0 | 0 | 44,094 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 0 | 41,510 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 22,317 | Withhold |
| Northern Trust | 0 | 0 | 0 | 21,499 | Withhold |
| Bridge Builder Trust | 18,778 | 0 | 0 | 0 | For |
| Pacific Life | 18,619 | 0 | 0 | 0 | For |
| Nationwide | 566 | 0 | 0 | 16,766 | Withhold |
| State Street | 0 | 0 | 0 | 16,681 | Withhold |
| Voya | 0 | 0 | 0 | 16,253 | Withhold |
| TARGET PORTFOLIO TRUST | 12,800 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 11,785 | 0 | Abstain |
| American Century | 0 | 0 | 0 | 10,895 | Withhold |
Showing the 25 largest of 38 asset managers. All 38 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
99.2% Approved · of votes cast
Prior year: 99.8% for (June 8, 2023 meeting) ▼ 0.6 pts
Description as filed by funds: Approval, on an advisory (non- binding) basis, of the compensation of our named executive officers.
GENERATION BIO CO.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers”): 47,772,176 for, 373,246 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, the stockholders of the Company approved, on an advisory (non-binding) basis, of the compensation of its named executive officers.”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 7,594,583 | 0 | 0 | 0 | For |
| Fidelity | 4,384,109 | 0 | 0 | 0 | For |
| Vanguard | 2,533,447 | 0 | 0 | 0 | For |
| BlackRock | 1,143,240 | 0 | 0 | 0 | For |
| Charles Schwab | 389,451 | 0 | 0 | 0 | For |
| Dimensional | 318,340 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 241,600 | 0 | 0 | Against |
| Goldman Sachs | 219,730 | 0 | 0 | 0 | For |
| SEI | 215,561 | 0 | 0 | 0 | For |
| Equitable | 178,978 | 0 | 0 | 0 | For |
| TIAA | 148,392 | 0 | 0 | 0 | For |
| John Hancock | 105,866 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 79,184 | 0 | 0 | 0 | For |
| Managed Portfolio Series | 44,094 | 0 | 0 | 0 | For |
| Lincoln Financial | 41,510 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 22,317 | 0 | 0 | 0 | For |
| Northern Trust | 21,499 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 18,778 | 0 | 0 | 0 | For |
| Pacific Life | 18,619 | 0 | 0 | 0 | For |
| Nationwide | 17,332 | 0 | 0 | 0 | For |
| State Street | 16,681 | 0 | 0 | 0 | For |
| Voya | 16,253 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 12,800 | 0 | 0 | 0 | For |
| Jackson National | 11,785 | 0 | 0 | 0 | For |
| American Century | 0 | 10,895 | 0 | 0 | Against |
Fund voting reports, all 38 managers: 17,587,014 for, 255,772 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 9,436,058 | 0 | 0 | 0 | For |
| Atlas Venture Life Science Advisors, LLC | 8,278,876 | 0 | 0 | 0 | For |
| Fidelity | 5,331,181 | 0 | 0 | 0 | For |
| EcoR1 Capital, LLC | 2,046,867 | 0 | 0 | 0 | For |
| PFM Health Sciences, LP | 1,622,487 | 0 | 0 | 0 | For |
| BlackRock | 1,125,147 | 593 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,069,389 | 0 | 0 | 0 | For |
| State Street | 917,755 | 46 | 0 | 0 | For |
| Goldman Sachs | 838,643 | 0 | 0 | 0 | For |
| Charles Schwab | 389,451 | 0 | 0 | 0 | For |
| Renaissance | 245,486 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 241,600 | 0 | 0 | Against |
| DE Shaw | 228,248 | 0 | 0 | 0 | For |
| SEI | 215,563 | 0 | 0 | 0 | For |
| JPMorgan | 214,254 | 0 | 0 | 0 | For |
| Northern Trust | 206,962 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 196,715 | 0 | 0 | 0 | For |
| Two Sigma | 194,837 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 175,974 | 0 | 0 | 0 | For |
| Nuveen | 150,965 | 0 | 0 | 0 | For |
| Yiheng Capital Management, L.P. | 149,976 | 0 | 0 | 0 | For |
| Dimensional | 123,594 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 81,207 | 0 | 0 | 0 | For |
| AllianceBernstein | 68,195 | 0 | 0 | 0 | For |
| Vanguard | 42,949 | 0 | 0 | 0 | For |
Institutional-manager reports, all 83 managers: 33,606,448 for, 295,658 against. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Approved · of votes cast
Prior year: 100.0% for (June 8, 2023 meeting) unchanged
Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
GENERATION BIO CO.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 53,562,165 for, 1,795 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, the stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm to serve for the year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 38 asset managers below reported 17,842,786 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 7,594,583 | 0 | 0 | 0 | For |
| Fidelity | 4,384,109 | 0 | 0 | 0 | For |
| Vanguard | 2,533,447 | 0 | 0 | 0 | For |
| BlackRock | 1,143,240 | 0 | 0 | 0 | For |
| Charles Schwab | 389,451 | 0 | 0 | 0 | For |
| Dimensional | 318,340 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 241,600 | 0 | 0 | 0 | For |
| Goldman Sachs | 219,730 | 0 | 0 | 0 | For |
| SEI | 215,561 | 0 | 0 | 0 | For |
| Equitable | 178,978 | 0 | 0 | 0 | For |
| TIAA | 148,392 | 0 | 0 | 0 | For |
| John Hancock | 105,866 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 79,184 | 0 | 0 | 0 | For |
| Managed Portfolio Series | 44,094 | 0 | 0 | 0 | For |
| Lincoln Financial | 41,510 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 22,317 | 0 | 0 | 0 | For |
| Northern Trust | 21,499 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 18,778 | 0 | 0 | 0 | For |
| Pacific Life | 18,619 | 0 | 0 | 0 | For |
| Nationwide | 17,332 | 0 | 0 | 0 | For |
| State Street | 16,681 | 0 | 0 | 0 | For |
| Voya | 16,253 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 12,800 | 0 | 0 | 0 | For |
| Jackson National | 11,785 | 0 | 0 | 0 | For |
| American Century | 10,895 | 0 | 0 | 0 | For |
Showing the 25 largest of 38 asset managers. All 38 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 66,528,840 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | T. Rowe Price | 11.42% |
| 2 | Fidelity | 6.59% |
| 3 | Vanguard | 3.81% |
| 4 | BlackRock | 1.72% |
| 5 | Charles Schwab | 0.59% |
| 6 | Dimensional | 0.48% |
| 7 | BRIDGEWAY FUNDS INC | 0.36% |
| 8 | Goldman Sachs | 0.33% |
| 9 | SEI | 0.32% |
| 10 | Equitable | 0.27% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | T. Rowe Price | 14.18% |
| 2 | Atlas Venture Life Science Advisors, LLC | 12.44% |
| 3 | Fidelity | 8.01% |
| 4 | EcoR1 Capital, LLC | 3.08% |
| 5 | PFM Health Sciences, LP | 2.44% |
| 6 | BlackRock | 1.69% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.61% |
| 8 | State Street | 1.38% |
| 9 | Goldman Sachs | 1.26% |
| 10 | Charles Schwab | 0.59% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| T. Rowe Price | 8,878,361 | 13.35% | Form 13F, quarter ended March 31, 2024 |
| Jason Rhodes | 8,386,826 | 12.61% | Proxy statement (DEF 14A), proxy filed April 24, 2024 |
| Entities affiliated with Atlas Venture Life Science Advisors | 8,278,876 | 12.44% | Proxy statement (DEF 14A), proxy filed April 24, 2024 |
| Entities affiliated with T Rowe Price Associates | 6,926,174 | 10.41% | Proxy statement (DEF 14A), proxy filed April 24, 2024 |
| ModernaTX | 5,859,375 | 8.81% | Proxy statement (DEF 14A), proxy filed April 24, 2024 |
| Entities affiliated with Fidelity Investment | 5,352,399 | 8.05% | Proxy statement (DEF 14A), proxy filed April 24, 2024 |
| Entities affiliated with BB Biotech AG | 3,608,280 | 5.42% | Proxy statement (DEF 14A), proxy filed April 24, 2024 |
| BB Biotech AG | 3,310,869 | 4.98% | Schedule 13G, filed December 9, 2024 |
| Geoff McDonough, M.D. | 2,553,239 | 3.84% | Proxy statement (DEF 14A), proxy filed April 24, 2024 |
| Geode Capital | 1,070,689 | 1.61% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 66,528,840 shares outstanding, as reported by GENERATION BIO CO. on its Form 10-Q dated May 8, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At GENERATION BIO CO.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 109 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 731 separate fund positions. On the most widely held item on that ballot — Approval, on an advisory (non- binding) basis, of the compensation of our named executive… — GENERATION BIO CO.'s filing reports the proposal as approved, with 99.2% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: GENERATION BIO CO.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 7, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from GENERATION BIO CO.’s 10-Q dated May 8, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
GENERATION BIO CO. proxy season coverage: 2023-2024 (this page) · 2024-2025.
Proxy Votes Now, “GENERATION BIO CO. 2024 Annual Meeting: Vote Results & How Funds Voted”, https://proxyvotesnow.com/company/generation-bio-co/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.